Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury

A nonclinical study from Stony Brook University reports evidence of activity across multiple animal models of neuropathic pain. The article does not provide company-specific financial details, trial timelines, or effect sizes, so near-term market impact appears limited.

Analysis

A nonclinical study from Stony Brook University reports evidence of activity across multiple animal models of neuropathic pain. The article does not provide company-specific financial details, trial timelines, or effect sizes, so near-term market impact appears limited.